Want to see HK:1875 full AI Analyst Report?
TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis
TOT BIOPHARM International Co. Ltd.
(HKEX:1875)
The score is held back primarily by weakening fundamentals (2025 revenue drop, return to losses, and persistently negative free cash flow). Technicals are broadly neutral with mixed moving-average positioning and only modest momentum signals. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.40B
- Dividend Yield
- ―
- Average Volume (3M)
- 566.22K
- Price to Earnings (P/E)
- -12.8
- Beta (1Y)
- 0.79
- Revenue Growth
- -51.10%
- EPS Growth
- -2384.76%
- Country
- Hong Kong
- Employees
- 596
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
Company Description
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key produc...
How the Company Makes Money
TOT BIOPHARM makes money primarily through revenue generated from its biopharmaceutical business activities, which typically include: (1) product-based revenue from sales of approved drugs and other pharmaceutical products, where available; (2) miles...
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
Summary
Financial performance is pressured by a sharp 2025 revenue decline (~32% YoY) and a swing back to meaningful losses after profitability in 2024. The balance sheet is relatively stable with manageable leverage, but cash quality is weak: operating cash flow weakened in 2025 and free cash flow remains persistently negative.
Income Statement
46NeutralBalance Sheet
62PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 501.12M | 747.64M | 1.10B | 780.63M | 442.18M | 76.33M |
| Gross Profit | 87.85M | 388.98M | 782.43M | 573.99M | 370.62M | 27.47M |
| EBITDA | -41.15M | -1.29M | 111.58M | 10.45M | -5.41M | -224.51M |
| Net Income | -162.14M | -100.37M | 34.76M | -37.76M | -49.92M | -261.22M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.26B | 1.51B | 1.43B | 1.26B | 710.26M |
| Cash, Cash Equivalents and Short-Term Investments | 263.69M | 328.47M | 381.26M | 351.60M | 517.63M | 155.38M |
| Total Debt | 350.93M | 383.72M | 395.47M | 345.65M | 289.53M | 208.56M |
| Total Liabilities | 558.84M | 633.75M | 779.12M | 739.41M | 546.59M | 375.17M |
| Stockholders Equity | 614.59M | 626.08M | 729.65M | 686.69M | 713.88M | 335.09M |
Cash Flow | ||||||
| Free Cash Flow | -94.39M | -26.93M | -7.17M | -146.77M | -180.19M | -290.45M |
| Operating Cash Flow | -66.11M | 16.14M | 116.40M | 56.43M | 59.93M | -175.14M |
| Investing Cash Flow | -30.45M | -43.07M | -122.50M | -164.10M | -282.76M | -108.39M |
| Financing Cash Flow | -27.89M | -25.66M | 34.18M | 38.23M | 481.24M | 212.08M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Negative. The current price of 3.31 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 3.71, and below the 200-day MA of 3.98, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 37.26 is Neutral, neither overbought nor oversold. The STOCH value of 32.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1875.
TOT BIOPHARM International Co. Ltd. Peers Comparison
Overall Rating
HK:269664.6Neutral
HK:215753Neutral
HK:996652Neutral- HK:187549Neutral
HK:187741.25Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1875 | 49Neutral | HKD 2.56B | -12.79 | -26.14% | ― | -51.10% | -2384.76% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1875 | TOT BIOPHARM International Co. Ltd. | 3.31 | 1.38 | 71.50% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
TOT BIOPHARM International Co. Ltd. Corporate Events
BioDlink’s CDMO Surge and WuXi XDC Deal Reshape Growth Strategy
BioDlink International Company Limited operates as a contract development and manufacturing organization in the biopharmaceutical sector, focusing on chemistry, manufacturing and controls projects and biologic drug production services. The company al...
BioDlink updates corporate logo while keeping shareholder arrangements unchanged
BioDlink International Company Limited has introduced a new corporate logo effective 11 August 2026, which will gradually appear on its interim and annual reports, stock exchange announcements, circulars, notices, share certificates and press release...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026